These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 8562348)
21. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Melcher AA; Mort D; Maughan TS Br J Cancer; 1996 Nov; 74(10):1651-4. PubMed ID: 8932350 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662 [TBL] [Abstract][Full Text] [Related]
23. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma. Cho EK; Lee WK; Lim DY; Bang SM; Park DK; Park YH; Kwon OS; Choi DJ; Shin DB; Lee JH; Lee TH J Korean Med Sci; 2002 Jun; 17(3):348-52. PubMed ID: 12068138 [TBL] [Abstract][Full Text] [Related]
24. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas. Sun W; Metz JM; Gallagher M; O'Dwyer PJ; Giantonio B; Whittington R; Haller DG Cancer Chemother Pharmacol; 2011 Mar; 67(3):621-7. PubMed ID: 20495918 [TBL] [Abstract][Full Text] [Related]
25. Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). Kucuk O; Pandya KJ; Skeel RT; Hochster H; Abeloff MD Breast Cancer Res Treat; 1999 Sep; 57(2):201-6. PubMed ID: 10598047 [TBL] [Abstract][Full Text] [Related]
26. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer. Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488 [TBL] [Abstract][Full Text] [Related]
27. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U; Wilke H; Seeber S Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897 [TBL] [Abstract][Full Text] [Related]
28. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659 [TBL] [Abstract][Full Text] [Related]
29. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517 [TBL] [Abstract][Full Text] [Related]
30. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966 [TBL] [Abstract][Full Text] [Related]
31. Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study. Bamias A; Cunningham D; Nicolson V; Norman A; Hill M; Nicolson M; O'Brien M; Webb A; Hill A Br J Cancer; 1995 Mar; 71(3):583-6. PubMed ID: 7880742 [TBL] [Abstract][Full Text] [Related]
32. Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study. Klaassen U; Wilke H; Müller C; Borquez D; Harstrick A; Seeber S Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-58-S17-60. PubMed ID: 9374095 [TBL] [Abstract][Full Text] [Related]
33. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin. Klaassen U; Wilke H; Seeber S J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323 [TBL] [Abstract][Full Text] [Related]
34. Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study. Humphreys AC; Dent J; Rodwell S; Crawford SM; Joffe JK; Bradley C; Dodwell D; Perren TJ Br J Cancer; 2004 Jun; 90(11):2131-4. PubMed ID: 15150554 [TBL] [Abstract][Full Text] [Related]
35. Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. Pentheroudakis G; Lim KC; Dunlop DJ; Soukop M; Eatock MM Acta Oncol; 2001; 40(7):855-61. PubMed ID: 11859986 [TBL] [Abstract][Full Text] [Related]
36. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D; J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656 [TBL] [Abstract][Full Text] [Related]
37. A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. Sirohi B; A'Hern R; Coombes G; Bliss JM; Hickish T; Perren T; Crawford M; O'Brien M; Iveson T; Ebbs S; Skene A; Laing R; Smith IE Ann Oncol; 2010 Aug; 21(8):1623-1629. PubMed ID: 20093351 [TBL] [Abstract][Full Text] [Related]
38. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study. Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173 [TBL] [Abstract][Full Text] [Related]
39. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM). Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648 [TBL] [Abstract][Full Text] [Related]
40. Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide. Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E; Zipoli T; Gonzalves L J Infus Chemother; 1996; 6(1):43-6. PubMed ID: 8748007 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]